“Promising blood tests deserve applause, with guardrails attached.”
“Plasma p-tau217 blood testing is as good as CSF or neuroimaging for diagnosing Alzheimer’s disease and will enable substantially earlier, broader diagnosis.”
Research and clinical guidance support the core point that some high-performing blood-based biomarker tests can accurately identify Alzheimer’s-related amyloid pathology and, in appropriate specialist settings, may substitute for CSF or amyloid PET. A blood draw is less invasive than a lumbar puncture. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12306682/?utm_source=openai))
The post overgeneralizes from specific validated tests and patient populations to “plasma p-tau217” broadly and to Alzheimer’s diagnosis overall. The FDA-cleared test measures a p-tau217/amyloid-beta ratio, is intended for cognitively impaired adults being assessed in specialized care, and must be interpreted with clinical information; it is not a stand-alone diagnostic or screening test. The statement that CSF is used to estimate plasma p-tau is backwards or unclear: CSF and blood are separate specimen types used to assess related biomarkers. ([fda.gov](https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease?utm_source=openai))
Material. Without the limits on assay, setting, symptoms, and confirmatory clinical assessment, a reasonable viewer could infer that any p-tau217 blood test can independently diagnose Alzheimer’s early in anyone.
Why Clear says this
The central message has a strong factual basis: p-tau217-based blood tests are an important, less-invasive diagnostic development and can perform comparably with CSF or PET in validated use cases. But the post leaves out boundaries that change how viewers should understand and use the claim. Current FDA guidance limits the cleared test to symptomatic patients in specialized evaluation and warns of false results; selected lots were also recalled after reports of excess positive or indeterminate classifications. ([fda.gov](https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease?utm_source=openai))
Evidence
- A 2025 Alzheimer’s Association guideline says blood tests meeting defined accuracy thresholds can substitute for CSF or amyloid PET in cognitively impaired patients presenting to specialized memory care. ([pmc.ncbi.nlm.nih.gov](https://pmc.ncbi.nlm.nih.gov/articles/PMC12306682/?utm_source=openai))
- A large independent study found one mass-spectrometry plasma %p-tau217 measure classified amyloid and tau PET status with very high accuracy in two cohorts, but this does not establish identical performance for every p-tau217 assay or population. ([nature.com](https://www.nature.com/articles/s41591-024-02869-z?utm_source=openai))
- The FDA cleared a p-tau217/amyloid-beta blood-test ratio in May 2025 as an aid to assessment in symptomatic adults aged 55 or older in specialized care—not as population screening or a stand-alone diagnosis. ([fda.gov](https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease?utm_source=openai))
- In February 2026, the FDA posted a Class II recall for specified lots of that test because of falsely elevated positive or indeterminate results, illustrating why assay-specific safeguards remain important. ([accessdata.fda.gov](https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfRes/res.cfm?id=217943&utm_source=openai))